ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Harbour BioMed's Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis
January 28, 2021Harbour BioMed (HBM), announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal antibody (mAb), for the treatment of adult patients with ... -
MG America Appoints Processing Division Sales Manager
June 12, 2019Wortham brings more than 15 years of experience managing sales of machinery, vision inspection and serialization solutions. -
Ra Pharma files $100M round as Soliris rival clears phase 2 trial
December 27, 2018Armed with a phase 2 win for its lead drug zilucoplan in rare disease myasthenia gravis (MG), Ra Pharma has pressed the button on a public funding round that it hopes could raise up to $115 million......
Pharma Sources Insight January 2025
